One of the presenters yesterday at the JPMorgan health care conference was pharmaceuticals company Dendreon , which is a stock that gets a lot of interest on Fool.com. Having already presented the bull side of the stock in a previous video, Motley Fool health care bureau chief Brenton Flynn now turns his attention to what Dendreon bears are honing in from the conference. He discusses the terse guidance coming from the company, how Dendreon's new approach to promoting Provenge could be wasteful, and advancing competition.
What's inside Supernova?
If you're an investor looking for big long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.
The article 3 Bearish Points Against This Biotech originally appeared on Fool.com.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.